InícioNotícias MundiaisVoyager Therapeutics inventory pops 30% on take care of Novartis

Voyager Therapeutics inventory pops 30% on take care of Novartis

Voyager Therapeutics stock chart


Key Factors

  • Voyager Therapeutics is a biotechnology firm specializing in gene therapies for neurological illnesses.
  • Voyager introduced a $1.3b licensing and gene remedy growth collaboration take care of Novartis to develop gene remedy applications for Huntington’s illness and ALS.
  • Voyager introduced a $100 million secondary providing of widespread inventory priced at $9.00.
  • 5 shares we like higher than Voyager Therapeutics

Voyager Therapeutics Inc. NASDAQ: VYGR is a biotech within the medical sector that makes a speciality of gene remedy for neurological illnesses. Its shares took a 30% spike on information of its partnership with Novartis AG NYSE: NVS. The deal is a collaboration and capsid licensing settlement price as much as $1.3 billion. It additionally validates Voyagers TRACER capsid discovery platform.

Whereas shares spiked to a excessive of $11.72 on Jan. 5, 2024, they rapidly fell on Jan. 5, 2024, with the announcement of a secondary providing of widespread inventory costs at $9.00 per share. The practice has returned to the station for buyers seeking to board.


Voyager Therapeutics

Whereas not a extensively recognized biotech, Voyager focuses on gene remedy growth, which seeks to switch or repair defective genes in neurological illness sufferers. Its pipeline consists of applications for amyotrophic lateral sclerosis (ALS), Parkinson’s illness, Alzheimer’s illness, and Huntington’s illness. Their lead candidate is VY-TAU01, an anti-tau antibody program for Alzheimer’s illness.

TRACER capsid discovery platform

Voyager developed its proprietary tropism redirection of AAV cell-type-specific expression RNA) TRACER capsid discovery platform. It’s an RNA-based screening platform that may rapidly find adeno-associated-virus (AAV) capsids within the mind. TRACER focuses on bettering the supply of genetic materials to particular places.

TRACER-generated AAV capsids are like tiny supply vans that may carry genetic materials into the mind and central nervous system (CNS) to achieve extremely tough areas. These deliveries are very focused and correct, so they do not find yourself in locations just like the liver or dorsal root ganglia. Voyager has licensed its next-generation TRACER capsids to help its collaboration companions’ gene remedy applications to deal with a variety of illnesses.


Novartis is not only GLP-1 medicine.

Novartis has been making headlines for its blockbuster GLP-1 weight-loss medicine Ozempic and Wegovy, that are taking the world by storm. Nevertheless, Novartis is energetic within the gene remedy section and in addition collaborates with Intellia Therapeutics Inc. NASDAQ: NTLA to develop superior CRISPR/Cas 9 gene-editing therapies using CAR-T cells. Try the sector heatmap on MarketBeat.

Novartis $1.3 billion collaboration deal

The partnership with Novartis and Voyager includes creating gene therapies for Huntington’s illness (HD), a hereditary situation the place nerve cells break down over time, and spinal muscular atrophy (SMA), a genetic situation for nerve cells within the spinal wire that controls voluntary muscle actions affecting a baby’s capacity to stroll, crawl and management head actions. Novartis positive factors entry to Voyager’s TRACER capsids to develop gene therapies.

Voyager will lead preclinical growth for HD, and Novartis will deal with medical growth and commercialization and safe international rights to Voyager’s AAV gene remedy for HD.

Monetary particulars of the Novartis partnership

Novartis can pay Voyager $100 million upfront, which features a $20 million buy of newly issued Voyager inventory and as much as $1.2 billion in funds for attaining preclinical, growth, regulatory, and gross sales milestones. On Jan. 5, 2023, Voyager priced a $100 million providing of widespread inventory, which included 7.779 million shares priced at $9.00 per share and three.33 million warrants. Get AI-powered insights on MarketBeat.

CEO feedback

Voyager Therapeutics CEO Dr. Alfred Sandrock Jr. commented, “Combining the confirmed capabilities of Novartis in gene remedy growth and commercialization with Voyager’s next-generation TRACER capsids and payloads may allow the development of essential new therapies for sufferers. As well as, the consideration Voyager will obtain from this collaboration will strengthen our stability sheet and lengthen our runway into mid-2026.”

Novartis, President of Biomedical Analysis, commented, “We consider Voyager’s TRACER capsids maintain promise for enabling next-generation gene therapies for illnesses of the central nervous system, aligning effectively with our deep neuroscience experience and gene remedy management at Novartis.”

Opera analyst rankings and value targets are at MarketBeat. Opera friends and competitor shares might be discovered with the MarketBeat inventory screener.

Voyager Therapeutics stock chart

 Day by day cup sample

The every day candlestick chart for VYGR illustrates a cup sample. The cup lip line fashioned at $10.32 on Sept.1, 2023. Shares offered off to a low of $6.06 on Nov. 13, 2023. VYGR staged a rally again up by way of its 50-period shifting common, stalling at its every day 200-period shifting common (MA) till the discharge of the Novartis deal.

Shares spiked to $11.72 earlier than collapsing again down in the direction of the $9.00 value degree, which was the $100 million secondary providing’s value degree. The every day relative energy index (RSI) fell sharply from the 80-band by way of the 60-base in the direction of the 70-band. Pullback assist ranges are at $8.59, $7.92, $7.21 and $6.41.   

Earlier than you think about Voyager Therapeutics, you will need to hear this.

MarketBeat retains monitor of Wall Avenue’s top-rated and greatest performing analysis analysts and the shares they suggest to their shoppers every day. MarketBeat has recognized the 5 shares that prime analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and Voyager Therapeutics wasn’t on the record.

Whereas Voyager Therapeutics presently has a “Average Purchase” score amongst analysts, top-rated analysts consider these 5 shares are higher buys.

View The 5 Shares Right here

(Almost) Everything You Need To Know About The EV Market Cover

Click on the hyperlink beneath and we’ll ship you MarketBeat’s information to investing in electrical car applied sciences (EV) and which EV shares present essentially the most promise.

Get This Free Report

Explore mais